Advancements in nanotechnology for targeted drug delivery in idiopathic pulmonary fibrosis: a focus on solid lipid nanoparticles and nanostructured lipid carriers

The integration of nanotechnology into anti-fibrotic therapy represents a significant advancement in addressing the challenges posed by IPF. By leveraging the unique properties of SLNs and NLCs, there is potential to overcome the limitations of current treatments and provide new therapeutic options that offer better management and improved outcomes for patients suffering from this debilitating disease.